Testing dapagliflozin and bosentan for large vessel vasculitis
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests two drugs, dapagliflozin and bosentan, to see if they help people with large vessel vasculitis who have been in remission for at least 6 months. The goal is to prevent flares and improve blood vessel health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with large vessel vasculitis and it has been stable (in remission) for 6 months or longer.
- You are 18 years or older.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You do not have congestive heart failure or a history of severe allergic reactions to similar drugs or foods.
- You are able and willing to attend study visits and give informed consent.
- You are not currently taking any medications that should not be taken with bosentan or dapagliflozin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with giant cell arteritis (GCA), a condition where blood vessels become inflamed. It tests a drug called rituximab to see if it can help by targeting special immune cells (B cells). The study uses scans to look at inflammation in the large blood vessels. You must have active GCA in the large vessels (shown by a scan in the last 4 weeks), be over 50, and start treatment with steroids alone (no other immune-suppressing drugs yet). You cannot have been on steroids for more than 4 weeks before joining.
This study tests whether bosentan, a medicine usually used for blood pressure in the lungs, can help control inflammation and symptoms in patients with giant cell arteritis (GCA). The goal is to see if it can reduce the need for steroids and improve quality of life.
This trial tests whether the drug upadacitinib can help people with giant cell arteritis (GCA) that affects the large blood vessels, such as the aorta. It is for those who have not responded to, cannot tolerate, or cannot use another treatment called tocilizumab.
This study tests a new type of PET/CT scanner (a imaging machine that takes detailed pictures of blood vessels) in patients newly diagnosed with large vessel vasculitis, a condition where large blood vessels become inflamed. The goal is to improve how doctors diagnose and monitor this condition.
This study uses PET and MRA scans to predict damage to large blood vessels in people who have or may have large vessel vasculitis (LVV). It aims to find at-risk patients early so they can get better care. You'll need to be willing to have both scans and come back for long-term check-ups.
This trial tests the drug tocilizumab (Actemra) to see if it helps reduce swelling in the aorta in people with giant cell arteritis (GCA) who are newly diagnosed or have had a flare. It may offer a targeted treatment for aortitis without using high-dose steroids.
Hear when a new Large Vessel Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.